查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566970

临床免疫分析仪市场：按类型、应用和最终用户分类：2024-2033 年全球机会分析和产业预测

Clinical Immunoanalyzer Market By Type , By Application By End user : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 216 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年临床免疫分析仪市值为47亿美元，预计2024年至2033年复合年增长率为5.5%，到2033年达到80亿美元。

临床免疫分析仪是医学实验室使用的诊断仪器，用于对患者样本中的各种免疫标记物（例如抗体、抗原和其他免疫系统成分）进行定量和定性分析。临床免疫分析仪透过提供准确、快速的结果，在诊断疾病、监测免疫反应和确定临床治疗策略方面发挥重要作用。这些分析仪可以快速提供测试结果，对于及时诊断和治疗决策至关重要。

全球临床免疫分析仪市场的成长是由癌症、自体免疫疾病和感染疾病等慢性病盛行率的惊人上升以及对早期和准确诊断的日益重视所推动的。根据研究，全球约20%的人口患有糖尿病、心血管疾病等慢性疾病，需要定期监测和诊断。因此，对能够有效检测相关生物标记的临床免疫分析仪的需求不断增长。此外，老年人口的快速成长是全球市场的主要驱动力。这是因为老年人更容易患各种疾病，这增加了对先进诊断解决方案的需求。根据世界卫生组织（WHO）的数据，2019年60岁以上的人口有10亿人。预计到 2030 年，这一数字将增至 14 亿，到 2050 年将增至 21 亿。随着老年人口的增加，慢性病的盛行率预计将显着增加。此外，人们对健康和预防性医疗保健的认识不断提高，正在推动先进诊断工具的使用，以实现更好的健康管理，从而促进市场成长。製造商专注于免疫分析仪自动化，以简化实验室工作流程、减少人为错误并提高通量。我们还将人工智慧和机器学习整合到我们的免疫分析仪中，以增强资料解释、自动化流程并提高诊断准确性。这些趋势极大地促进了先进诊断设备采用率的提高。然而，先进免疫分析仪的初始投资和维护成本较高，以及需要定期维护、校准和技术支持，限制了市场成长。此外，许多国家没有足够的医疗设施来满足其公民的需求，而有限的医疗服务是市场的主要阻碍因素。另一方面，检测技术的不断改进，提高了灵敏度和特异性，使生物标记的检测更加准确和可靠，可能有利于预测期内全球市场的扩张。此外，新兴市场医疗基础设施的开拓正在推动这些地区临床免疫分析仪的采用并扩大市场规模。

全球临床免疫分析仪产业按类型、应用、最终用户和地区细分。按类型划分，市场分为 ELISA、CLIA、RIA 等。依用途分为临床化学、内分泌、肿瘤、感染疾病诊断、循环系统等。依最终用户划分，可分为医院/诊所、诊断实验室、研究机构等。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按类型划分，ELISA 细分市场预计将在 2024 年至 2033 年期间占据市场主导地位。

从应用来看，感染疾病诊断预计将成为预测期内的主要部分。

医院和诊所预计将成为未来几年临床免疫分析仪的主要最终用户。

按地区划分，临床免疫分析仪市场在不久的将来可能会在北美出现显着成长。

该报告可以定制。

  • 监管指引
  • 根据客户兴趣新增其他公司简介
  • 平均销售价格分析/价格分布分析
  • 扩大公司简介列表
  • 赎回场景

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章临床免疫分析仪市场：依类型

  • 市场概况
  • ELISA
  • CLIA
  • RIA
  • 其他的

第五章临床免疫分析仪市场：依应用分类

  • 市场概况
  • 临床化学
  • 内分泌学
  • 肿瘤学
  • 感染疾病诊断
  • 循环系统
  • 其他的

第六章 临床免疫分析仪市场：依最终使用者分类

  • 市场概况
  • 医院和诊所
  • 诊断实验室
  • 研究所
  • 其他的

第七章临床免疫分析仪市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国临床免疫分析仪市场
    • 加拿大临床免疫分析仪市场
    • 墨西哥临床免疫分析仪市场
  • 欧洲
    • 主要市场趋势和机会
    • 法国临床免疫分析仪市场
    • 德国临床免疫分析仪市场
    • 义大利临床免疫分析仪市场
    • 西班牙临床免疫分析仪市场
    • 英国临床免疫分析仪市场
    • 其他欧洲临床免疫分析仪市场
  • 亚太地区
    • 主要市场趋势和机会
    • 中国临床免疫分析仪市场
    • 日本临床免疫分析仪市场
    • 印度临床免疫分析仪市场
    • 韩国临床免疫分析仪市场
    • 澳洲临床免疫分析仪市场
    • 其他亚太临床免疫分析仪市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西临床免疫分析仪市场
    • 南非临床免疫分析仪市场
    • 沙乌地阿拉伯临床免疫分析仪市场
    • 其他拉丁美洲/中东/非洲临床免疫分析仪市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • Roche Diagnostics Corporation
  • Abbott
  • Siemens AG.
  • Beckman Coulter
  • Ortho-Clinical Diagnostics
  • Bio-Rad
  • BioMerieux
  • DiaSorin SpA
  • Werfen Life
  • Thermo Fisher Scientific
简介目录
Product Code: A324391

The clinical immunoanalyzer market was valued at $4.7 billion in 2023, and is projected to reach $8.0 billion by 2033, growing at a CAGR of 5.5% from 2024 to 2033.

Clinical immunoanalyzer is a diagnostic instrument used in medical laboratories to perform quantitative and qualitative analyses of various immunological markers such as antibodies, antigens, and other immune system components in patient samples. By providing accurate and rapid results, clinical immunoanalyzers play a critical role in diagnosing diseases, monitoring immune responses, and guiding treatment decisions in clinical settings. These analyzers deliver quick turnaround times for test results, which is crucial for timely diagnosis and treatment decisions.

The growth of the global clinical immunoanalyzer market is driven by alarming rise in prevalence of chronic conditions such as cancer, autoimmune diseases, and infectious diseases and increase in emphasis on early and precise diagnosis. Studies have shown that approximately 20% of the global population suffers from chronic diseases such as diabetes and cardiovascular disorders, which require regular monitoring and diagnostics. This drives the demand for clinical immunoanalyzers capable of efficiently detecting relevant biomarkers. Furthermore, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fact that aged individuals are highly susceptible to various diseases, which fosters the need for advanced diagnostic solutions. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. With increasing aged population, the incidence of chronic conditions is expected to rise significantly. Moreover, increase in awareness about health and preventive care promotes the use of advanced diagnostic tools for better health management, which augments the market growth. Manufacturers are focusing on automation of immunoanalyzers to streamline laboratory workflows, reduce human error, and increase throughput as well as integration of AI and ML into immunoanalyzers to enhance data interpretation, automate processes, and improve diagnostic accuracy. These trends are notably contributing to higher adoption rates of advanced diagnostic equipment. However, high initial investment and maintenance costs of advanced immunoanalyzers and need for regular maintenance, calibration, and technical support restrain the market growth. Moreover, lack of appropriate health facilities to meet population needs in most countries and limited access act as the key deterrent factors of the market. On the contrary, ongoing improvements in assay technologies are leading to higher sensitivity and specificity to enable more accurate and reliable detection of biomarker are expected to offer lucrative opportunities for expansion of the global market during the forecast period. Furthermore, development of healthcare infrastructure in emerging markets is driving the adoption of clinical immunoanalyzers in these regions, expanding market reach.

The global clinical immunoanalyzer industry is segmented into type, application, end user, and region. On the basis of type, the market is categorized into ELISA, CLIA, RIA, and others. Depending on application, it is categorized into clinical chemistry, endocrinology, oncology, infectious disease diagnostics, cardiology, and others. By end user, it is fragmented into hospitals & clinics, diagnostic laboratories, research institutes, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the ELISA segment is expected to dominate the market from 2024 to 2033.

On the basis of application, infectious disease diagnostics is anticipated to emerge as the leading segment during the forecast period.

The hospitals & clinics segment is projected to serve as the major end user of clinical immunoanalyzers in the coming years.

Region wise, the clinical immunoanalyzer market is likely to experience significant growth across North America in the near future.

Competition Analysis

Competitive analysis and profiles of the major players in the global clinical immunoanalyzer market include Roche Diagnostics Corporation, Abbott, Siemens AG., Beckman Coulter, Ortho-Clinical Diagnostics, Bio-Rad, bioMerieux, DiaSorin S.p.A., Werfen Life, and Thermo Fisher Scientific. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and strengthen their foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Average Selling Price Analysis / Price Point Analysis
  • Expanded list for Company Profiles
  • Reimbursement Scenario

Key Market Segments

By Type

  • ELISA
  • CLIA
  • RIA
  • Others

By Application

  • Clinical Chemistry
  • Endocrinology
  • Oncology
  • Infectious Disease Diagnostics
  • Cardiology
  • Others

By End User

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Roche Diagnostics Corporation
    • Abbott
    • Siemens AG.
    • Beckman Coulter
    • Ortho-Clinical Diagnostics
    • Bio-Rad
    • bioMerieux
    • DiaSorin S.p.A.
    • Werfen Life
    • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CLINICAL IMMUNOANALYZER MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. ELISA
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. CLIA
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. RIA
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Others
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country

CHAPTER 5: CLINICAL IMMUNOANALYZER MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Clinical Chemistry
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Endocrinology
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Oncology
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Infectious Disease Diagnostics
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Cardiology
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country
  • 5.7. Others
    • 5.7.1. Key Market Trends, Growth Factors and Opportunities
    • 5.7.2. Market Size and Forecast, By Region
    • 5.7.3. Market Share Analysis, By Country

CHAPTER 6: CLINICAL IMMUNOANALYZER MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals And Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Research Institutes
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Others
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: CLINICAL IMMUNOANALYZER MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Clinical Immunoanalyzer Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Clinical Immunoanalyzer Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Clinical Immunoanalyzer Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Clinical Immunoanalyzer Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. Germany Clinical Immunoanalyzer Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. Italy Clinical Immunoanalyzer Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Spain Clinical Immunoanalyzer Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. UK Clinical Immunoanalyzer Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Clinical Immunoanalyzer Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Clinical Immunoanalyzer Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. Japan Clinical Immunoanalyzer Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Clinical Immunoanalyzer Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. South Korea Clinical Immunoanalyzer Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. Australia Clinical Immunoanalyzer Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Clinical Immunoanalyzer Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Clinical Immunoanalyzer Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. South Africa Clinical Immunoanalyzer Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. Saudi Arabia Clinical Immunoanalyzer Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Clinical Immunoanalyzer Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Roche Diagnostics Corporation
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Abbott
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Siemens AG.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Beckman Coulter
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Ortho-Clinical Diagnostics
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Bio-Rad
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. BioMerieux
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. DiaSorin S.p.A.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Werfen Life
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Thermo Fisher Scientific
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments